Item 2.02 Results of Operations and Financial Condition.
On January 6, 2023, Ocular Therapeutix, Inc. (the "Company") issued a press
release (the "Release") to provide a business update. A copy of the Release is
included as Exhibit 99.1 hereto and is incorporated by reference herein.
Although the Company is currently in the process of finalizing its financial
results for the quarter and year ended December 31, 2022, the Company disclosed
in the Release preliminary estimates as to net product revenue for the quarter
and year ended December 31, 2022 and cash and cash equivalents as of
December 31, 2022. The estimated net product revenue and cash and cash
equivalents figures are based on preliminary and unaudited information and
management's estimates as of the date of this Current Report on Form 8-K and are
subject to completion of the Company's financial closing procedures. The
Company's independent registered public accounting firm has not conducted an
audit or review of, and does not express an opinion or any other form of
assurance with respect to, the estimated net product revenue and cash and cash
equivalents figures.
The information in this Current Report on Form 8-K is furnished to comply with
Item 2.02 of Form 8-K, and shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as expressly set forth by specific
reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
99.1 Press Release of Ocular Therapeutix, Inc., dated January 6, 2023
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
© Edgar Online, source Glimpses